Ann: Optimisation of Monepantel Uptake, page-12

Brilliant!  So in very simple terms, PAA have spent some time developing a drug that’s on market for entirely something different (intestinal worms), found other  indications for a drug that was basicically used for worming (treating cancer with minimal side effects) but showed resistance after a relatively short period of time to intestinal worms (useless to big Pharma for that indication), & repurposed this, which took quite some time to get right & work out optimum dosage, timing & half-life, also whether food is a contributing factor to drug absorption, plus of course palatabilty, for indication in cancer treatment.  (nausea & vomiting an important symptoms to treat on top of pain & tumours).

Exipients & co-factors are important in bioavailability of the active drug in any medication (ie different effect of taking generics, so the same dose of active drug, however can have different bioavailability).  Hence efficacy & half-life both in how drugs are manufactured & dietary effects (before or after food).  Not to mention IP & marketability in Veterinary Medicine/Oncology. 

Just think when humans have gone to the chemist & Pharmacist tells you it’s the same drug (yes it is) only cheaper buying generics.  Often it’s not the same bioavailability due to these & google that, it’s a thing.  I’ve formally reported a few myself (humans).

The hard yards appear to be done now.  On to clinical trials soon & dose of 2-3 times a week with one tablet for B cell lymphoma is really amazing.

Not sure if anyone has discussed this, but for veterinary trial sites, maybe they will require a short day stay to monitor vomiting of tablets (dogs do this easily ) as it will affect data in clinical trials.  

GLTAH...it’s been quite a long haul (not for me, but much respect), but perfecting a medication before PH2 when you already have safety data & the possibility of fast tracking this to market & already having a deal with Elanco & 80% owned by Eli Lilly...how often do we see failed drugs repurposed or used more regularly for other indications than what they were intended for, that have been highly successful. GLTAH